Ory Rouvio

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Yaël C. Cohen, Mor Zada, Shuang-Yin Wang et al. · Nature Medicine · 2021 · 246 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

Drorit Merkel, Kalman Filanovsky, Anat Gafter‐Gvili et al. · American Journal of Hematology · 2012 · 68 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +13

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

Eli Muchtar, Moshe E. Gatt, Ory Rouvio et al. · British Journal of Haematology · 2015 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

Yaël C. Cohen, Hila Magen, Noa Lavi et al. · Annals of Hematology · 2020 · 23 citations

Medicine, Oncology, Pharmacology +12